Premium
Clonal selection of CD56 + t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biological marker?
Author(s) -
Daniels Jasmine T.,
Davis Brad J.,
HoudeMcGrail Lisa,
Byrd John C.
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01711.x
Subject(s) - cytarabine , medicine , oncology , bone marrow , leukemia , gastroenterology
Although patients with acute myelogenous leukaemia (AML) and t(8;21)(q22;q22) have a favourable prognosis, a subset die despite receiving appropriate treatment. Recent reports suggest that expression of the CD56 antigen might predict for both extramedullary disease and poor outcome in these patients. We describe a patient who presented with CD56‐negative t(8;21) AML who achieved a complete remission and was subsequently treated with three consolidative courses of high‐dose cytarabine therapy. She relapsed 9 months later with extramedullary and bone marrow involvement of CD56‐positive t(8;21) AML. This case demonstrates clonal evolution and provides further support that blast expression of CD56 might be an unfavourable prognostic factor in t(8;21) AML.